heterogeneity of nsclc and precipitating oncogenic driver mutations
Published 5 years ago • 657 plays • Length 16:35Download video MP4
Download video MP3
Similar videos
-
1:30
what are driver mutations vs passenger mutations?
-
3:44
what is a driver mutation?
-
26:57
segment 2: molecular targets in nsclc
-
5:29
the role of driver mutations in nsclc treatment - 2022 program: lcvl
-
18:41
extreme rare mutations in lung cancer (ros1, trk, her2): treatment opportunities
-
3:39
what is driver and passenger mutation: role in cancer formation.
-
4:44
understanding non-small cell lung cancer
-
5:59
diagnostic testing for genetic mutations in lung cancer
-
1:13
targeting oncogenes in nsclc
-
13:06
managing t790-negative egfr-mutated nsclc
-
4:09
impact of driver mutations in nsclc
-
1:14
dr. brahmer on targeting driver mutations in nsclc
-
26:13
therapeutic algorithm for nsclc adenocarcinoma
-
37:23
nsclc: integrating egfr-inhibiting therapies into clinical pathways for first-line treatment
-
32:26
nsclc: interactive case-based panel discussion
-
6:04
the future of driver mutations in nsclc
-
58:42
managing lung cancer heterogeneity - jason akulian - 20180124
-
44:56
advanced nsclc: refining clinical pathways in the rapidly evolving therapeutic landscape
-
6:14
understanding biomarker testing in non-small cell lung cancer
-
20:35
tki-resistant egfr-mutant nsclc
-
8:03
driver mutations trump pd-l1 expression in lung adenocarcinoma